| human | Q5 |
| P6178 | Dimensions author ID | 0712447302.96 |
| P496 | ORCID iD | 0000-0002-9894-1049 |
| P1153 | Scopus author ID | 8596721900 |
| P108 | employer | Burnet Institute | Q3151717 |
| P734 | family name | Gray | Q1544042 |
| Gray | Q1544042 | ||
| Gray | Q1544042 | ||
| P735 | given name | Lachlan | Q7705746 |
| Lachlan | Q7705746 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q36827946 | A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations |
| Q36180179 | A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA. |
| Q35274763 | Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages |
| Q34987062 | An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes |
| Q34008699 | Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. |
| Q43941310 | Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy |
| Q35400103 | CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates |
| Q36690585 | CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm |
| Q35069459 | Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues |
| Q33857491 | Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry |
| Q43480510 | Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection |
| Q33838633 | Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. |
| Q35436367 | Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy. |
| Q57235590 | Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders |
| Q34545588 | Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele |
| Q39619066 | Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia |
| Q34009029 | HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production |
| Q35109157 | HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. |
| Q35009720 | HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research |
| Q38071699 | Is specific HIV eradication from the brain possible or needed? |
| Q34792976 | Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. |
| Q62572416 | Longitudinal Analysis ofnef/Long Terminal Repeat–Deleted HIV‐1 in Blood and Cerebrospinal Fluid of a Long‐Term Survivor Who Developed HIV‐Associated Dementia |
| Q36476641 | Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5 |
| Q35924919 | Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source |
| Q48073666 | Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge |
| Q36554035 | Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats |
| Q28486204 | The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes |
| Q39163578 | The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets |
| Q37191794 | Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain |
| Q45413895 | Transcriptional activity of blood-and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia |
| Q39031676 | Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome |
Search more.